经济动物学报2025,Vol.29Issue(6):468-473,6.DOI:10.13326/j.jea.2025.1905
梅花鹿水胎和乳胎对血虚证小鼠的改善作用
Ameliorative Effects of Water Fetus and Milk Fetus of Sika Deer on Blood Deficiency Syndrome in Mice
摘要
Abstract
To investigate the ameliorative effects of sika deer water fetus and milk fetus on mice with blood deficiency syndrome,a mouse model of blood deficiency syndrome was established using cyclophosphamide combined with busulfan.The mice were orally administered water fetus powder and milk fetus powder for 16 days.At days 8,10,12,14 and 16,intraperitoneal injections of 40 mg/kg cyclophosphamide and 20 mg/kg busulfan were administered.Sixty minutes after the last injection,blood was collected from the orbital sinus,and the mice were sacrificed by cervical dislocation.The spleen and thymus were excised,weighed,and their organ indices were calculated.The counts of peripheral red blood cells(RBC),hemoglobin(HGB),and platelets(PLT)were measured.Serum levels of IL-2,IL-6,AST and ALT,as well as splenic levels of CAT,SOD and MDA were detected.Results showed that compared with the model group,both water fetus and milk fetus increased the counts of peripheral RBC,HGB and PLT,improved the spleen and thymus indices,increased serum IL-2 levels,decreased IL-6,AST and ALT levels,enhanced splenic CAT and SOD activities,and reduced MDA content.Compared with the high-dose milk fetus group,the high-dose water fetus group showed 4.36%and 8.39%increase in splenic CAT and SOD levels,respectively,and 8.09%decrease in MDA content.These results indicated that both sika deer water fetus and milk fetus had ameliorative effects on cyclophosphamide and busulfan-induced blood deficiency syndrome in mice,and the water fetus exhibited superior therapeutic efficacy.关键词
梅花鹿/水胎/乳胎/血虚证/改善作用Key words
sika deer/water fetus/milk fetus/blood deficiency/improvement effect分类
农业科技引用本文复制引用
YU Yang,LIU Xingyi,SUN Qiang,BAI Chen,LI Zhiman,LI Wei,SUN Yinshi..梅花鹿水胎和乳胎对血虚证小鼠的改善作用[J].经济动物学报,2025,29(6):468-473,6.基金项目
国家重点研发计划项目(2018YFC1706604,2018YFC1706605) (2018YFC1706604,2018YFC1706605)